{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T09:39:52Z","timestamp":1775727592106,"version":"3.50.1"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Key Lab of Wenzhou city-Gynecological Oncology","award":["ZD201603"],"award-info":[{"award-number":["ZD201603"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Life Sciences"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1016\/j.lfs.2017.12.018","type":"journal-article","created":{"date-parts":[[2017,12,13]],"date-time":"2017-12-13T18:17:53Z","timestamp":1513189073000},"page":"34-39","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"special_numbering":"C","title":["Prognostic values of excision repair cross-complementing genes mRNA expression in ovarian cancer patients"],"prefix":"10.1016","volume":"194","author":[{"given":"Menghuang","family":"Zhao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saisai","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lulu","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qi","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haiyan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8389-928X","authenticated-orcid":false,"given":"Xueqiong","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.lfs.2017.12.018_bb0005","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21387","article-title":"Cancer statistics, 2017","volume":"67","author":"Siegel","year":"2017","journal-title":"CA Cancer J. Clin."},{"issue":"17","key":"10.1016\/j.lfs.2017.12.018_bb0010","doi-asserted-by":"crossref","first-page":"29395","DOI":"10.18632\/oncotarget.12561","article-title":"The role of the androgen receptor in ovarian cancer carcinogenesis and its clinical implications","volume":"8","author":"Zhu","year":"2017","journal-title":"Oncotarget"},{"issue":"1\u20132","key":"10.1016\/j.lfs.2017.12.018_bb0015","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0027-5107(99)00020-2","article-title":"Repair of DNA lesions: mechanisms and relative repair efficiencies","volume":"424","author":"Braithwaite","year":"1999","journal-title":"Mutat. Res."},{"issue":"5","key":"10.1016\/j.lfs.2017.12.018_bb0020","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1111\/IGC.0b013e3181a12e09","article-title":"The relationship of platinum resistance and ERCC1 protein expression in epithelial ovarian cancer","volume":"19","author":"Steffensen","year":"2009","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"12","key":"10.1016\/j.lfs.2017.12.018_bb0025","first-page":"1513","article-title":"Polymorphisms in DNA repair genes and associations with cancer risk","volume":"11","author":"Goode","year":"2002","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"issue":"10","key":"10.1016\/j.lfs.2017.12.018_bb0030","first-page":"1993","article-title":"Expression and clinical implication of Beclin1, HMGB1, p62, survivin, BRCA1 and ERCC1 in epithelial ovarian tumor tissues","volume":"20","author":"Ju","year":"2016","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"issue":"2","key":"10.1016\/j.lfs.2017.12.018_bb0035","doi-asserted-by":"crossref","first-page":"857","DOI":"10.3892\/ol.2016.4732","article-title":"High ERCC1 expression is associated with platinum-resistance, but not survival in patients with epithelial ovarian cancer","volume":"12","author":"Du","year":"2016","journal-title":"Oncol. Lett."},{"issue":"25","key":"10.1016\/j.lfs.2017.12.018_bb0040","doi-asserted-by":"crossref","first-page":"40152","DOI":"10.18632\/oncotarget.10308","article-title":"Cumulative defects in DNA repair pathways drive the PARP inhibitor response in high-grade serous epithelial ovarian cancer cell lines","volume":"8","author":"Fleury","year":"2017","journal-title":"Oncotarget"},{"issue":"8","key":"10.1016\/j.lfs.2017.12.018_bb0045","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1038\/sj.bjc.6604317","article-title":"ERCC1 mRNA levels and survival of advanced gastric cancer patients treated with a modified FOLFOX regimen","volume":"98","author":"Wei","year":"2008","journal-title":"Br. J. Cancer"},{"issue":"1","key":"10.1016\/j.lfs.2017.12.018_bb0050","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.ejca.2007.09.006","article-title":"ERCC1 predicting chemoradiation resistance and poor outcome in oesophageal cancer","volume":"44","author":"Kim","year":"2008","journal-title":"Eur. J. Cancer"},{"issue":"7","key":"10.1016\/j.lfs.2017.12.018_bb0055","first-page":"2286","article-title":"Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer","volume":"8","author":"Lord","year":"2002","journal-title":"Clin. Cancer Res."},{"issue":"13","key":"10.1016\/j.lfs.2017.12.018_bb0060","doi-asserted-by":"crossref","first-page":"4225","DOI":"10.1158\/1078-0432.CCR-07-4848","article-title":"Patients with ERCC1-negative locally advanced esophageal cancers may benefit from preoperative chemoradiotherapy","volume":"14","author":"Kim","year":"2008","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.lfs.2017.12.018_bb0065","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1093\/annonc\/mdl435","article-title":"Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy","volume":"18","author":"Bellmunt","year":"2007","journal-title":"Ann. Oncol."},{"issue":"19","key":"10.1016\/j.lfs.2017.12.018_bb0070","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1200\/JCO.2006.09.7915","article-title":"Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer","volume":"25","author":"Cobo","year":"2007","journal-title":"J. Clin. Oncol."},{"issue":"23","key":"10.1016\/j.lfs.2017.12.018_bb0075","doi-asserted-by":"crossref","first-page":"4298","DOI":"10.1200\/JCO.2001.19.23.4298","article-title":"ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy","volume":"19","author":"Shirota","year":"2001","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.lfs.2017.12.018_bb0080","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1200\/JCO.1998.16.1.309","article-title":"ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy","volume":"16","author":"Metzger","year":"1998","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.lfs.2017.12.018_bb0085","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0082241","article-title":"Online survival analysis software to assess the prognostic value of biomarkers using transcriptomic data in non-small-cell lung cancer","volume":"8","author":"Gyorffy","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.lfs.2017.12.018_bb0090","doi-asserted-by":"crossref","first-page":"5087","DOI":"10.2147\/DDDT.S87197","article-title":"Distinct prognostic values and potential drug targets of ALDH1 isoenzymes in non-small-cell lung cancer","volume":"9","author":"You","year":"2015","journal-title":"Drug Des. Devel. Ther."},{"issue":"10","key":"10.1016\/j.lfs.2017.12.018_bb0095","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1080\/15592294.2015.1078049","article-title":"Low expression of ITIH5 in adenocarcinoma of the lung is associated with unfavorable patients' outcome","volume":"10","author":"Dotsch","year":"2015","journal-title":"Epigenetics"},{"issue":"12","key":"10.1016\/j.lfs.2017.12.018_bb0100","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0115609","article-title":"Mining CK2 in cancer","volume":"9","author":"Ortega","year":"2014","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/j.lfs.2017.12.018_bb0105","article-title":"GREB1 functions as a growth promoter and is modulated by IL6\/STAT3 in breast cancer","volume":"7","author":"Liu","year":"2012","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.lfs.2017.12.018_bb0110","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.1074\/mcp.M112.023861","article-title":"Proteomic signatures of acquired letrozole resistance in breast cancer: suppressed estrogen signaling and increased cell motility and invasiveness","volume":"12","author":"Tilghman","year":"2013","journal-title":"Mol. Cell. Proteomics"},{"issue":"2","key":"10.1016\/j.lfs.2017.12.018_bb0115","doi-asserted-by":"crossref","first-page":"R45","DOI":"10.1186\/bcr3144","article-title":"Proteomic analysis of acquired tamoxifen resistance in MCF-7 cells reveals expression signatures associated with enhanced migration","volume":"14","author":"Zhou","year":"2012","journal-title":"Breast Cancer Res."},{"issue":"5","key":"10.1016\/j.lfs.2017.12.018_bb0120","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1369\/0022155413480148","article-title":"Elevated BUBR1 expression is associated with poor survival in early breast cancer patients: 15-year follow-up analysis","volume":"61","author":"Maciejczyk","year":"2013","journal-title":"J. Histochem. Cytochem."},{"issue":"4","key":"10.1016\/j.lfs.2017.12.018_bb0125","first-page":"513","article-title":"Elevated nuclear S100P expression is associated with poor survival in early breast cancer patients","volume":"28","author":"Maciejczyk","year":"2013","journal-title":"Histol. Histopathol."},{"issue":"2","key":"10.1016\/j.lfs.2017.12.018_bb0130","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s12253-011-9449-9","article-title":"ABCC2 (MRP2, cMOAT) localized in the nuclear envelope of breast carcinoma cells correlates with poor clinical outcome","volume":"18","author":"Maciejczyk","year":"2012","journal-title":"Pathol. Oncol. Res."},{"issue":"1","key":"10.1016\/j.lfs.2017.12.018_bb0135","first-page":"5","article-title":"New prognostic factors in breast cancer","volume":"22","author":"Adam Maciejczyk","year":"2013","journal-title":"Adv. Clin. Exp. Med."},{"issue":"2","key":"10.1016\/j.lfs.2017.12.018_bb0140","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s00280-014-2635-1","article-title":"Prognostic relevance of carbonic anhydrase IX expression is distinct in various subtypes of breast cancer and its silencing suppresses self-renewal capacity of breast cancer cells","volume":"75","author":"Ivanova","year":"2015","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"4","key":"10.1016\/j.lfs.2017.12.018_bb0145","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1007\/s13277-014-2852-6","article-title":"Distinct prognostic values of ALDH1 isoenzymes in breast cancer","volume":"36","author":"Wu","year":"2015","journal-title":"Tumour Biol."},{"key":"10.1016\/j.lfs.2017.12.018_bb0150","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1186\/s12885-015-1569-2","article-title":"Elevated C1orf63 expression is correlated with CDK10 and predicts better outcome for advanced breast cancers: a retrospective study","volume":"15","author":"Hong","year":"2015","journal-title":"BMC Cancer"},{"issue":"2","key":"10.1016\/j.lfs.2017.12.018_bb0155","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.molonc.2014.09.010","article-title":"Deletion at 6q24.2-26 predicts longer survival of high-grade serous epithelial ovarian cancer patients","volume":"9","author":"Kamieniak","year":"2015","journal-title":"Mol. Oncol."},{"issue":"1","key":"10.1016\/j.lfs.2017.12.018_bb0160","first-page":"e7","article-title":"The NER-related gene GTF2H5 predicts survival in high-grade serous ovarian cancer patients","volume":"27","author":"Gayarre","year":"2016"},{"key":"10.1016\/j.lfs.2017.12.018_bb0165","article-title":"Prognostic values of four notch receptor mRNA expression in gastric cancer","volume":"6","author":"Wu","year":"2016","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.lfs.2017.12.018_bb0170","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1530\/ERC-11-0329","article-title":"Implementing an online tool for genome-wide validation of survival-associated biomarkers in ovarian-cancer using microarray data from 1287 patients","volume":"19","author":"Gyorffy","year":"2012","journal-title":"Endocr. Relat. Cancer"},{"issue":"5","key":"10.1016\/j.lfs.2017.12.018_bb0175","first-page":"339","article-title":"Enhanced cisplatin cytotoxicity by RNA interfering the excision repair cross-complementing 1 gene in ovarian cancer cell lines","volume":"41","author":"Liu","year":"2006","journal-title":"Zhonghua Fu Chan Ke Za Zhi"},{"issue":"7","key":"10.1016\/j.lfs.2017.12.018_bb0180","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1089\/dna.2015.2805","article-title":"Lentivirus-mediated RNAi silencing targeting ERCC1 reverses cisplatin resistance in cisplatin-resistant ovarian carcinoma cell line","volume":"34","author":"Du","year":"2015","journal-title":"DNA Cell Biol."},{"issue":"2","key":"10.1016\/j.lfs.2017.12.018_bb0185","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.ygyno.2012.01.008","article-title":"Pre-treatment tumor expression of ERCC1 in women with advanced stage epithelial ovarian cancer is not predictive of clinical outcomes: a gynecologic oncology group study","volume":"125","author":"Rubatt","year":"2012","journal-title":"Gynecol. Oncol."},{"issue":"9","key":"10.1016\/j.lfs.2017.12.018_bb0190","doi-asserted-by":"crossref","first-page":"4474","DOI":"10.1158\/0008-5472.CAN-06-4076","article-title":"A gynecologic oncology group study of platinum-DNA adducts and excision repair cross-complementation group 1 expression in optimal, stage III epithelial ovarian cancer treated with platinum-taxane chemotherapy","volume":"67","author":"Darcy","year":"2007","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.lfs.2017.12.018_bb0195","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.ygyno.2010.07.018","article-title":"Excision repair cross-complementation group 1 protein overexpression as a predictor of poor survival for high-grade serous ovarian adenocarcinoma","volume":"119","author":"Scheil-Bertram","year":"2010","journal-title":"Gynecol. Oncol."},{"issue":"8","key":"10.1016\/j.lfs.2017.12.018_bb0200","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/j.ejca.2008.12.013","article-title":"A randomised, double-blind, phase II study of two doses of pemetrexed in the treatment of platinum-resistant, epithelial ovarian or primary peritoneal cancer","volume":"45","author":"Vergote","year":"2009","journal-title":"Eur. J. Cancer"},{"issue":"5","key":"10.1016\/j.lfs.2017.12.018_bb0205","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.3892\/ijo.2014.2311","article-title":"Resistance to first line platinum paclitaxel chemotherapy in serous epithelial ovarian cancer: the prediction value of ERCC1 and tau expression","volume":"44","author":"Steffensen","year":"2014","journal-title":"Int. J. Oncol."},{"issue":"6","key":"10.1016\/j.lfs.2017.12.018_bb0210","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/nrm3350","article-title":"TFIIH: when transcription met DNA repair","volume":"13","author":"Compe","year":"2012","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"1","key":"10.1016\/j.lfs.2017.12.018_bb0215","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.5301\/jbm.5000186","article-title":"Increased expression of ERCC2 gene in head and neck cancer is associated with aggressive tumors: a systematic review and case-control study","volume":"31","author":"Zafeer","year":"2016","journal-title":"Int. J. Biol. Markers"},{"issue":"1","key":"10.1016\/j.lfs.2017.12.018_bb0220","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.yexmp.2017.01.006","article-title":"ERCC1 and ERCC2 as predictive biomarkers to oxaliplatin-based chemotherapy in colorectal cancer patients from Egypt","volume":"102","author":"Kassem","year":"2017","journal-title":"Exp. Mol. Pathol."},{"issue":"4","key":"10.1016\/j.lfs.2017.12.018_bb0225","first-page":"827","article-title":"Excision repair cross complementing 3 expression is involved in patient prognosis and tumor progression in esophageal cancer","volume":"12","author":"Terashita","year":"2004","journal-title":"Oncol. Rep."},{"issue":"7","key":"10.1016\/j.lfs.2017.12.018_bb0230","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/j.dnarep.2011.04.022","article-title":"Regulation of endonuclease activity in human nucleotide excision repair","volume":"10","author":"Fagbemi","year":"2011","journal-title":"DNA Repair (Amst)"},{"issue":"1","key":"10.1016\/j.lfs.2017.12.018_bb0235","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.ijrobp.2011.05.033","article-title":"DNA repair biomarkers predict response to neoadjuvant chemoradiotherapy in esophageal cancer","volume":"83","author":"Alexander","year":"2012","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"23","key":"10.1016\/j.lfs.2017.12.018_bb0240","doi-asserted-by":"crossref","first-page":"5796","DOI":"10.1158\/1078-0432.CCR-10-0292","article-title":"DNA repair protein biomarkers associated with time to recurrence in triple-negative breast cancer","volume":"16","author":"Alexander","year":"2010","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.lfs.2017.12.018_bb0245","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1055\/s-2002-33189","article-title":"Expression of genes of potential importance in the response to chemotherapy in osteosarcoma patients","volume":"214","author":"Nathrath","year":"2002","journal-title":"Klin. Padiatr."},{"issue":"18","key":"10.1016\/j.lfs.2017.12.018_bb0250","doi-asserted-by":"crossref","first-page":"2952","DOI":"10.1200\/JCO.2007.13.5806","article-title":"ERCC5 is a novel biomarker of ovarian cancer prognosis","volume":"26","author":"Walsh","year":"2008","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.lfs.2017.12.018_bb0255","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/j.ejca.2010.11.029","article-title":"Expression of DNA repair genes in ovarian cancer samples: biological and clinical considerations","volume":"47","author":"Ganzinelli","year":"2011","journal-title":"Eur. J. Cancer"},{"issue":"1","key":"10.1016\/j.lfs.2017.12.018_bb0260","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.canlet.2008.08.002","article-title":"ERCC6\/CSB gene polymorphisms and lung cancer risk","volume":"273","author":"Ma","year":"2009","journal-title":"Cancer Lett."},{"issue":"2","key":"10.1016\/j.lfs.2017.12.018_bb0265","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1002\/cncr.10231","article-title":"Expression of nucleotide excision repair genes and the risk for squamous cell carcinoma of the head and neck","volume":"94","author":"Cheng","year":"2002","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.lfs.2017.12.018_bb0270","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1093\/carcin\/21.8.1527","article-title":"Reduced expression levels of nucleotide excision repair genes in lung cancer: a case-control analysis","volume":"21","author":"Cheng","year":"2000","journal-title":"Carcinogenesis"},{"issue":"4","key":"10.1016\/j.lfs.2017.12.018_bb0275","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.molcel.2006.06.029","article-title":"Cockayne syndrome a and B proteins differentially regulate recruitment of chromatin remodeling and repair factors to stalled RNA polymerase II in vivo","volume":"23","author":"Fousteri","year":"2006","journal-title":"Mol. Cell"},{"issue":"2","key":"10.1016\/j.lfs.2017.12.018_bb0280","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/sj.emboj.7600933","article-title":"Initiation of DNA repair mediated by a stalled RNA polymerase IIO","volume":"25","author":"Laine","year":"2006","journal-title":"EMBO J."}],"container-title":["Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320517306562?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320517306562?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,4,5]],"date-time":"2021-04-05T07:17:21Z","timestamp":1617607041000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0024320517306562"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":56,"alternative-id":["S0024320517306562"],"URL":"https:\/\/doi.org\/10.1016\/j.lfs.2017.12.018","relation":{},"ISSN":["0024-3205"],"issn-type":[{"value":"0024-3205","type":"print"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prognostic values of excision repair cross-complementing genes mRNA expression in ovarian cancer patients","name":"articletitle","label":"Article Title"},{"value":"Life Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lfs.2017.12.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}